HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease.
Tanvetyanon T, Chen DT, Gray JE. HER-2 Altered Early-Stage Non-Small Cell Lung Cancer Had Better Survival than Triple-Negative Disease. J Clin Med. 2026 May.15(9). Pubmedid: 42123214 . Pmcid: PMC13164032.
— 2026cited by 0position: selected
Tanvetyanon T, Joshi U, Chen DT, Gray JE. Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis. JCO Oncol Pract. 2026 Mar.22(3):410-417. Pubmedid: 40472300 .
— 2026cited by 0position: selected
Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Chatterjee D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodrigues Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real-world s
— 2026cited by 0position: selected
Lantz AE, Gebert R, Li J, Oliveras JA, Gordián ER, Perez-Morales J, Eschrich S, Chen DT, Rosa M, Dutil J, Saavedra HI, Muñoz-Antonia T, Flores I, Cress WD. Worse Clinical and Survival Outcomes in Breast Cancer Patients Living in Puerto Rico Compared to Hispanics, Non-Hispanic Blacks, and Non-Hispani
— 2026cited by 0position: selected
Ozakinci H, Desai B, Kalos D, Chen DT, Henry M, Solanki H, Boyle TA, Trejo Bittar HE, Nazario GS, Haura EB, Marusyk A, Pellini B. Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in KRAS -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumors. Transl Lung Canc
— 2026cited by 0position: selected
Tanvetyanon T, Chen DT, Gray JE. Relationship between PD-L1 Expression and Outcomes of Salvage Treatment Following Durvalumab Consolidation. Clin Lung Cancer. 2026 Apr.27(3):135-143. Pubmedid: 41238478 .
— 2026cited by 0position: selected
Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.
The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma
Phase 1 trial of hypofractionated stereotactic re-irradiation in combination with nivolumab, ipilimumab, and bevacizumab for recurrent high-grade gliomas.
A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade glioma.
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma.
Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Patients from Puerto Rico and Florida.
Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis.
Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.
The Impact of Edema on Skeletal Muscle Changes among Patients with Pancreatic Ductal Adenocarcinoma.
DeSomma A, Maletz S, Basinski TL, Morales R, de Castria TB, Bloomston M, Chen DT, Douglas WG, Huguet KL, Jeong D, Jiang K, Kim DW, Luthra A, Pimiento JM, Rajasekhara S, Velanovich V, Park MA, Shields GS, Slavich GM, Permuth JB. Lifetime stressor exposure and depression among patients with pancreatic
— 2025cited by 0position: selected
Lantz AE, Gordián ER, Rosa M, Rodríguez Ruíz M, Johnson JO, Gebert R, Bahr A, Chen DT, Dutil J, Li J, Oliveras Torres JA, Saavedra HI, Eschrich SA, Flores I, Cress WD. Creation and Characterization of a Breast Cancer Tissue Microarray Including Black and White Patients from Florida and Hispanic Pati
— 2025cited by 0position: selected
Glazar DJ, Sahebjam S, Yu HM, Chen DT, Bhandari M, Enderling H. A sample size analysis of a mathematical model of longitudinal tumor volume and progression-free survival for Bayesian individual dynamic predictions in recurrent high-grade glioma. CPT Pharmacometrics Syst Pharmacol. 2025 Mar.14(3):495
— 2025cited by 0position: selected
Marin-Acevedo JA, Thapa R, Bandikatla SV, Chen DT, Hicks JK, Gray JE, Puri S. Outcomes with frontline immune checkpoint inhibitors among individuals with BRAF-mutant non-small cell lung cancer. Front Oncol. 2025 Dec.15:1681119. Pubmedid: 41450930 . Pmcid: PMC12727587.
— 2025cited by 0position: selected
Tanvetyanon T, Chen DT, Gray JE. Timing of Durvalumab Consolidation and Survival in Non-Small Cell Lung Cancer: A Population-Based Analysis. JCO Oncol Pract. 2025 Dec.OP2500259. Pubmedid: 41370737 .
— 2025cited by 0position: selected
Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Dhrubo D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodriguez-Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real world survi
— 2025cited by 0position: selected
Tarhini AA, Obermayer A, Lee SJ, LaFramboise WA, Hodi FS, Karunamurthy AD, Eljilany I, Chen DT, Hwu P, El Naqa IM, Streicher H, Sondak VK, Storkus WJ, Butterfield LH, Shaw TI, Kirkwood JM. Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power
— 2025cited by 0position: selected
Leveraging real-world data to predict cancer cachexia stage, quality of life, and survival in a racially and ethnically diverse multi-institutional cohort of treatment-naïve patients with pancreatic ductal adenocarcinoma
Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas.
Pancreatic Cyst Size Measurement on Magnetic Resonance Imaging Compared to Pathology.
Molecular Pathway and Immune Profile Analysis of IPMN-Derived versus PanIN-Derived Pancreatic Ductal Adenocarcinomas
Ozakinci H, Song X, Nazario GS, Lila T, Chen B, Simpson T, Nguyen JV, Moran Segura CM, Thompson ZJ, Thapa R, Rose TA, Haura EB, Pellini B, Yu X, Ruffell BH, Chen DT, Boyle TA, Beg AA. Rapid Autopsy to Define Dendritic Cell Spatial Distribution and T Cell Association in Lung Adenocarcinoma. J Immunol
— 2024cited by 0position: selected
Tanvetyanon T, Chen DT, Gray JE. Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis. Clin Lung Cancer. 2024 Nov.25(7):e304-e311. Pubmedid: 38825406 .
— 2024cited by 0position: selected
Phase 1 Dose Escalation of Stereotactic Body Radiation Therapy and Concurrent Cisplatin for Reirradiation of Unresectable, Recurrent Squamous Cell Carcinoma of the Head and Neck